Clinical trialsCompany release

Entrada reports Q3 Duchenne progress, orphan status for ENTR-601-45 and cash of $193M

🇺🇸 Entrada Therapeutics, Inc. (TRDA) · Thu 05 Nov 2026

Entrada Therapeutics says ELEVATE-45-201 Cohort 1 met its safety and tolerability objective, with Cohort 2 data for both Duchenne programmes expected in the first half of 2027.

Entrada Therapeutics reported third-quarter 2026 results on 5 November, alongside an update on its two Duchenne muscular dystrophy candidates, ENTR-601-44 and ENTR-601-45.

The company said Cohort 1 of the ELEVATE-45-201 trial met its safety and tolerability objective. The summary available does not give detailed trial data, so no further efficacy or safety figures can be reported here.

Separately, the US Food and Drug Administration's Office of Orphan Products Development granted orphan drug designation to ENTR-601-45. As general context, orphan designation is given to products intended for rare diseases and can bring development incentives, but it is not a marketing authorisation.

Entrada reported cash of $193.0 million at 30 September 2026. The company's headline says this funds operations into the fourth quarter of 2027.

On timelines, Cohort 2 readouts are expected in the first quarter of 2027 for ELEVATE-44-201 and in the first half of 2027 for ELEVATE-45-201.

What it means for your team

  • The orphan designation for ENTR-601-45 is a regulatory milestone for the programme, but it does not indicate approval or a particular review outcome.
  • Safety and tolerability results from ELEVATE-45-201 Cohort 1 will be of interest to pharmacovigilance teams tracking early-stage Duchenne therapies; detailed data were not in the material reviewed.
  • Cohort 2 readouts in Q1 and H1 2027 are the next datapoints for teams monitoring the Duchenne pipeline and competitive landscape.
  • The stated cash runway into Q4 2027 covers the expected readout window.

Company's press release (SEC filing): Entrada Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Entrada Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →